Rakovina Stock Based Compensation from 2010 to 2024
RKV Stock | CAD 0.08 0.01 23.08% |
Stock Based Compensation | First Reported 2010-12-31 | Previous Quarter 129.3 K | Current Value 202 K | Quarterly Volatility 75.7 K |
Check Rakovina Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Rakovina Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 158.9 K, Interest Income of 21.7 K or Selling General Administrative of 706.8 K, as well as many indicators such as . Rakovina financial statements analysis is a perfect complement when working with Rakovina Therapeutics Valuation or Volatility modules.
Rakovina | Stock Based Compensation |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Rakovina Stock Analysis
When running Rakovina Therapeutics' price analysis, check to measure Rakovina Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rakovina Therapeutics is operating at the current time. Most of Rakovina Therapeutics' value examination focuses on studying past and present price action to predict the probability of Rakovina Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rakovina Therapeutics' price. Additionally, you may evaluate how the addition of Rakovina Therapeutics to your portfolios can decrease your overall portfolio volatility.